Leerink Partnrs Has Negative Outlook of Vericel Q4 Earnings

Vericel Co. (NASDAQ:VCEL) – Equities researchers at Leerink Partnrs decreased their Q4 2024 earnings per share (EPS) estimates for shares of Vericel in a note issued to investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the biotechnology company will earn $0.32 per share for the quarter, down from their previous estimate of $0.33. The consensus estimate for Vericel’s current full-year earnings is $0.13 per share. Leerink Partnrs also issued estimates for Vericel’s Q4 2025 earnings at $0.36 EPS, FY2025 earnings at $0.38 EPS, FY2026 earnings at $0.80 EPS, FY2027 earnings at $1.34 EPS and FY2028 earnings at $1.79 EPS.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The firm had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million.

Other equities research analysts also recently issued reports about the stock. BTIG Research increased their price objective on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday. Canaccord Genuity Group started coverage on shares of Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 price target for the company. TD Cowen raised their price objective on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $60.00 price target on shares of Vericel in a research report on Tuesday, November 19th. Finally, StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.71.

Vericel Stock Performance

VCEL stock opened at $58.75 on Tuesday. The company has a market capitalization of $2.90 billion, a PE ratio of 979.17 and a beta of 1.66. Vericel has a 52 week low of $32.31 and a 52 week high of $61.49. The company’s 50-day simple moving average is $46.69 and its 200 day simple moving average is $47.14.

Insider Activity at Vericel

In other news, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the transaction, the director now directly owns 11,000 shares in the company, valued at approximately $443,850. This represents a 34.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the transaction, the director now directly owns 26,595 shares in the company, valued at $1,595,700. This trade represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,666 shares of company stock valued at $1,350,764 over the last 90 days. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of Vericel

Institutional investors and hedge funds have recently bought and sold shares of the business. International Assets Investment Management LLC increased its holdings in shares of Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 619 shares in the last quarter. CWM LLC increased its holdings in shares of Vericel by 319.0% during the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 504 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 322 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in shares of Vericel during the 3rd quarter valued at approximately $92,000.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.